Aruvant appoints new CEO
19 November 2019 -

Aruvant, a clinical-stage gene therapy company focused on haematological conditions, announced on Tuesday that William Chou, MD has been appointed as chief executive officer.

In this role, Dr Chou will lead Aruvant as the company prepares to dose the next cohort of patients with ARU-1801, a potentially curative investigational gene therapy for sickle cell disease administered with only reduced intensity conditioning.

Dr Chou most recently was vice president, Global Disease Lead for Novartis' Cell and Gene Therapy unit, overseeing the global commercial launch of Kymriah, the first CAR-T cell therapy. He also led the Kymriah lymphoma clinical development program to approvals in the US, Europe, Australia, Canada and Japan. Prior to that he served in a variety of leadership roles at Novartis across both development and commercial functions.

Before joining Novartis, Dr Chou worked at the Boston Consulting Group where he focused on commercial and clinical pharmaceutical strategy.